BeiGene Announces Acceptance and Priority Review by Health Canada of New Drug Submission for BRUKINSA® (zanubrutinib) in Waldenström’s Macroglobulinemia
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--$BGNE #BGNE--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company…